immunotherapy – Medxy AI

Why Do Chimpanzees Rarely Get Cancer? Unveiling a Key Evolutionary Difference That Could Revolutionize Immunotherapy

By MedXY 09/14/2025

New research reveals that a protein called plasmin weakens human immune response against cancer compared to chimpanzees, offering promising strategies to enhance cancer immunotherapy.

Clinical Updates Wellness & Lifestyle

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

By MedXY 09/09/2025

The KEYNOTE-585 trial adding pembrolizumab to perioperative chemotherapy did not significantly improve event-free survival in esophagogastric cancer, while the MATTERHORN trial showed durvalumab plus FLOT chemotherapy improves outcomes, establishing a new standard of care.

Clinical Updates Wellness & Lifestyle

Updated Phase III HARMONi Trial Data Reveal Enhanced Survival Benefits of Ivonescimab in NSCLC

By MedXY 09/07/2025

Recent updates from the global Phase III HARMONi study demonstrate envafolimab’s significant improvement in overall and progression-free survival in NSCLC, with consistent benefits across diverse populations, reinforcing its emerging role in lung cancer therapy.

Clinical Updates Wellness & Lifestyle

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY 09/04/2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatments.

Clinical Updates Wellness & Lifestyle

Targeting Immunosenescence: Combining Senolytics with Immunotherapy Improves Outcomes in Head and Neck Squamous Cell Carcinoma

By MedXY 09/04/2025

A phase 2 trial reveals that senolytic agents combined with anti-PD-1 immunotherapy enhance pathological response rates in head and neck squamous cell carcinoma by mitigating immunosenescence, with promising safety profiles.

Clinical Updates Wellness & Lifestyle

Promising Immunotherapy Combination Shows Durable Responses in Advanced Gynecological Clear Cell Cancers

By MedXY 08/23/2025

A nonrandomized trial reveals that combined nivolumab and ipilimumab treatment achieves a 54% response rate with durable effects in advanced ovarian and endometrial clear cell cancers, addressing critical unmet therapeutic needs.

Clinical Updates Wellness & Lifestyle

High-Dose Vitamin C Induces Pyroptosis in LKB1-Mutant Lung Cancer and Enhances Immunotherapy Response

By MedXY 08/23/2025

New research reveals that high-dose vitamin C selectively kills LKB1-mutant NSCLC cells by inducing pyroptosis, reversing immunotherapy resistance and improving T cell infiltration through GLUT1-mediated uptake and ROS-mediated cell death.

Clinical Updates Wellness & Lifestyle

Emerging Roles of Circular RNAs in Cancer and Immunotherapy: Mechanisms and Clinical Potential

By MedXY 08/21/2025

Circular RNAs (circRNAs) are pivotal regulators in cancer biology and immunotherapy, acting through mechanisms such as miRNA sponging, protein interactions, and translation. Their modulation of tumor immune microenvironment offers promising therapeutic avenues despite current technical challenges.

Clinical Updates Wellness & Lifestyle

Adjuvant Cemiplimab in High-Risk Cutaneous Squamous-Cell Carcinoma: A Review of Recent Evidence and Clinical Implications

By MedXY 08/21/2025

Adjuvant cemiplimab significantly improves disease-free survival in patients with high-risk cutaneous squamous-cell carcinoma post-surgery and radiotherapy, reducing locoregional and distant recurrences compared to placebo, with manageable toxicity.

Clinical Updates Wellness & Lifestyle

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Squamous-Cell Carcinoma: A Phase 3 Trial Overview and Clinical Implications

By MedXY 08/19/2025

The phase 3 KEYNOTE-689 trial demonstrates that adding perioperative pembrolizumab to surgery and adjuvant therapy significantly improves event-free survival in locally advanced HNSCC without compromising surgical outcomes or safety.